BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 32817141)

  • 1. Diagnostic Accuracy of
    Sprute K; Kramer V; Koerber SA; Meneses M; Fernandez R; Soza-Ried C; Eiber M; Weber WA; Rauscher I; Rahbar K; Schaefers M; Watabe T; Uemura M; Naka S; Nonomura N; Hatazawa J; Schwab C; Schütz V; Hohenfellner M; Holland-Letz T; Debus J; Kratochwil C; Amaral H; Choyke PL; Haberkorn U; Sandoval C; Giesel FL
    J Nucl Med; 2021 Feb; 62(2):208-213. PubMed ID: 32817141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection Efficacy of
    Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
    J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of [
    Mingels C; Bohn KP; Rominger A; Afshar-Oromieh A; Alberts I
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2436-2444. PubMed ID: 35067735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 9. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of
    Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
    Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
    Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
    Hope TA; Eiber M; Armstrong WR; Juarez R; Murthy V; Lawhn-Heath C; Behr SC; Zhang L; Barbato F; Ceci F; Farolfi A; Schwarzenböck SM; Unterrainer M; Zacho HD; Nguyen HG; Cooperberg MR; Carroll PR; Reiter RE; Holden S; Herrmann K; Zhu S; Fendler WP; Czernin J; Calais J
    JAMA Oncol; 2021 Nov; 7(11):1635-1642. PubMed ID: 34529005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraindividual Comparison of
    Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
    J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
    [No Abstract]   [Full Text] [Related]  

  • 18. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical Recurrence of Prostate Cancer: Initial Results with [
    Giesel FL; Will L; Kesch C; Freitag M; Kremer C; Merkle J; Neels OC; Cardinale J; Hadaschik B; Hohenfellner M; Kopka K; Haberkorn U; Kratochwil C
    J Nucl Med; 2018 Apr; 59(4):632-635. PubMed ID: 29419475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
    J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.